Collegium Pharmaceutical, Inc.
COLLHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bullish as of May 28
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The $1.08B market capitalization puts COLL squarely in small-cap range for its industry. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Market Cap
$1.08B
Beta
0.76
P/E (TTM)
16.20
P/E (Fwd)
4.38
EPS (TTM)
$2.06
EPS (Fwd)
$7.61
ROE
27.4%
ROA
7.6%
Cash
$421.8M
Total Debt
$929.7M
Free CF
$332.6M
52W Change
14.5%
Annual Financials
Cash vs Debt
The company holds $421.8M in cash, though total debt stands at $929.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $332.6M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 27.4% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $463.9M (2022) to $780.6M (2025), reflecting a 68% increase over the period.
Investors considering Collegium Pharmaceutical, Inc. should weigh the typical risks associated with COLL's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing COLL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.